Phase 1 CARDINAL trial evaluating TERN-701 in 2L+ CML patients remains ongoing, with interim data from initial cohorts anticipated in second half of 2024 FOSTER CITY, Calif., April 29, 2024 (GLOBE ...
CARMEL, Ind.--(BUSINESS WIRE)--Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results